U.S. Markets open in 3 hrs 20 mins

Incyte Corporation (INCY)

NASDAQ Global Select - NASDAQ Global Select Delayed Price. Currency in USD
Add to watchlist
123.86+2.97 (+2.46%)
At close: 4:00PM EDT
People also watch
VRTXBMRNALXNREGNSGEN
  • M
    Michael-P
    Michael-P

    Tax repatriation holiday in the works... will spur bio-tech M&A...

    ... "“repatriation”, would tax corporate earnings that are being stored abroad when that money returns to the U.S. and use the money to modernize the country’s infrastructure. " (The Hill)

    http://thehill.com/policy/transportation/347361-dem-lawmaker-renews-push-for-infrastructure-tax-package

    Imageidolos-frases
  • A
    Anonymous
    Anonymous
    Week ana half to ESMO abstract release. What we're looking for is ECHO 204 "final" report. We already know that the ORR will be 65+% (vs historical in the 40s for Keytruda alone). In the earlier reports, all responses were ongoing. If that continues, well, from my keyboard to G.d's eye. But anything over 50% would be excellent. From the way Merck responded after the results were in, I'd guess that it'll be 60-80% (this can be tricky to gin up a historical comparison for, because there's a superposition of the usual relapse distribution over a substantial "no relapse" number for Keytruda).

    Since I'm a bull, that 60+ or so is the number of ongoing responses that I think would generate enthusiasm for Incyte. Essentially, a repeat of 65+% ORR and 60+% persistence of response as of the interim review of the phase 3 (probably Spring '18) would support "invoking the slaughter rule" and getting epac to market most of a year earlier than generally anticipated.
  • T
    Tom
    Tom
    sell the rips will continue until, retake of 200dma, to many taken to the woodshed on margin
  • T
    Tom
    Tom
    119s again on L2, going back to lod
  • m
    madeoff
    madeoff
    Maddi: Buy out any day now, ooooooooooo ok?
    Maddi -- $140 yet?
  • T
    Tom
    Tom
    hey hey hey, ibb GREEN, dow GREEN, s&P GREEN, NAZ, basically even.....INCY RED yet again....lower highs and lower lows STILL IN PLAY
  • M
    Michael-P
    Michael-P
    Look at that - above the 200 mda ... Look again, rising stock price... INCY Rising all the way into Labor Day weekend, as will the S&P & DOW...Let the runners run... INCY is on sale, lots of buying kicking in.
    Imageidolos-frases
  • T
    Tom
    Tom
    no retake of 200dma ,more new lows coming
  • A
    Anonymous
    Anonymous
    Thing about trading ranges--that's where the stock price is when nothing's happening. No need for an explanation of any move within the range. Now, in the last week we've had let's see...sharpest war scare in a few years, disappointing result of a competitor's IO drug combo trial, disassembly of US executive (with a pot-shot at drug pricing tweeted out), domestic terrorism, foreign terrorism.... And a lot of INCY is in "hot stock"-oriented portfolios, which are weak hands by definition. Seems like plenty of reasons for leaving the channel, all real and all unrelated to the actual business of Incyte.

    And for all that, INCY is still above the post-CRL low.
  • M
    Michael-P
    Michael-P

    Ongoing trials with Opdivo:

    "Bristol-Myers Squibb’s 2Q17 Update: Opdivo Could Drive Growth" ... with label expansion, Epacadostat use would also grow...

    http://marketrealist.com/2017/08/bristol-myers-squibbs-opdivo-could-be-a-long-term-growth-driver/

    Bristol-Myers Squibb’s Opdivo Could Be a Long-Term Growth Driver - Market Realist
    In June 2017, Bristol-Myers Squibb presented the clinical trial data of its Phase 1/2 ECHO-204 trial.
    marketrealist.com
  • D
    DQSjr
    DQSjr
    Imagerazle-dazle
  • T
    Tom
    Tom
    ESMO will be nothing more pump and dump, just like, ASH, ASOC,AARC
  • T
    Tom
    Tom
    where is 140?????
  • w
    wereinayelllowsubmarine
    wereinayelllowsubmarine
    The week started with a low at $118 on about the same volume as it rose today, which is half. If you're trading then the day to day isn't the problem. The problem is if you're long on INCY because the trend is down and the down trend is just starting.

    Remember that chart? Look at the chart from end of 2015 to start of 2016, see what volatility looks like? Now look at the chart from March up till today. Big correction coming. Like I said, sub $100 by the EOY. I hope the kool aid was good while it lasted.

    Just so you know, I didn't post when it touched $118 out of courtesy, because I didn't want to kick you while you were down.

    But remember when this bounced back to $130, and the pump squad dusted off their favorite songs about $140, $150, and buyouts? Did you sing along with them? But remember how I was telling you it was temporary? Who got it right? So I'll try again here and tell you that everything in the $120's is temporary too. I'm not kidding or exaggerating just to be mean when I say sub $100, that's really where this overhyped one trick pony is headed. Inflation only gets you so far before the bubble pops. No one is looking at INCY's horrendous 250-300 P/E and wishing they could get the "scoop" at 400 P/E. If they want INCY all they have to do is wait and they can get it at a harsh discount. With INCY's extravagant spending and paltry earnings INCY will soon have to make some unsavory decisions, how do you think the market reacts when they announce cuts in programs and forecasts? And everyone is watching the record highs in the market, and everyone is waiting for it to crumble. Good luck.
  • B
    B
    B
    Imagecomfort-ings
  • A
    Anonymous
    Anonymous
    On the subject of range-bound, take a look at INCY's price behavior since the post-CRL bottom. I see lower highs and higher lows, which is pretty much the definition of drifting.

    Of course, I expect the ESMO abstract release to be the next catalyst. If it is disappointing (say, less than 6-month median response duration), there could be a meaningful drop. That's sorta within the realm of possibility, but in that case you'd really have expected Merck to have gone with 2 smaller phase 3s (best approach for eventual approval) rather than one large one (offers possibilities of shortcuts if results are dramatic). If the abstract reveals mildly favorable results, it should basically just shift the range upward by about as much as the apparent disagreement between Incyte and Lilly on what to do about responding to the CRL shifted it down. Spectacular results (>80% of responses continuing at data cutoff) could generate a pop.

    Obvious wild card in the near term is response to the CRL. As before, ANYTHING that decreases uncertainty would be good (although a lawsuit against FDA might turn my face minty green). I see that NCT02265705, the phase 3 for Chinese licensing, is being kept open, now about 10 months after final data collection. There's probably no result from that trial that could turn FDA around, but an outcome announcement would open a path to Chinese sales and quite possibly (since the analysis would mostly have been done post-CRL) give a strong clue to what the parties intend to do moving forward.

    Not much from the deep pipeline figures to move the needle, but in the front-row pipeline I don't think there's been a full presentation of the studies that led to the itacitinib ('110) trial against GvHD (NCT03139604). The preliminary presentation was good, but not spectacular. Still, since the leak about existence of '110 was one of the hammer blows in "The Bad Conference Call," it would be a pleasant irony to see news about the same candidate restore the prior uptrend.
  • M
    Michael-P
    Michael-P

    Gilead: Road To $100 -- From Seekingalpha

    "...Incyte makes a lot of sense and isn’t a ton of ‘risk’ in that it has an impressive portfolio and pipeline, much of which have plenty of overlap with Gilead’s existing products... Incyte is the long and steady play."

    https://seekingalpha.com/article/4100043-gilead-road-100?auth_param=1e7tqa:1cpdohc:1b0bc8d8f7c81398d02afcf133477c0d&uprof=45&dr=1#alt1

    Gilead: Road To $100
    Gilead might have an activist investor.Dan Loeb fits the mold.He’ll push for a buyout and there are two prime candidates.
    seekingalpha.com
  • T
    Tom
    Tom
    selling into every rip, means cleaning out all those on margin
  • D
    DQSjr
    DQSjr
    We must be getting close to a deal...Tommy's negative posts have increased and he really comes out in force on down days. Is he anxious? Worried? Working for the group putting a deal together? Conspiracy? Nobody hangs around since the low teens getting hammered calling for a fall in SP this long. Who's buying INCY Tommy??
  • M
    Maddison
    Maddison
    OT..Please pray for the injured/deceased in Barcelona today... The barbaric terrorists in this world must not win!